ALS drug study halted: brain scans aimed to reveal inflammation changes
NCT ID NCT04066244
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 28 times
Summary
This study looked at a drug called BLZ945 in people with ALS, a nerve disease that weakens muscles. The goal was to check safety and see if the drug changes brain inflammation using special PET scans. About 28 adults with ALS were planned to join, but the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Turku, 20520, Finland
-
Novartis Investigative Site
Stockholm, 14186, Sweden
-
Yale University School of Medicine
New Haven, Connecticut, 06520-8048, United States
Conditions
Explore the condition pages connected to this study.